secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-04-10T23:59:59+00:00
Accession:  0001564590-23-005548
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana appoints Douglas Williams as President of R&D and Gary Meininger as CMO; CMO Sunil Agarwal departs
--------------------------------------------------------------------------------

- Douglas Williams, Ph.D., appointed EVP & President, R&D effective April 10, 2023; previously CEO of Codiak BioSciences.
- Gary Meininger, M.D., appointed Chief Medical Officer; previously SVP, Head of Clinical Development at Vertex.
- Sunil Agarwal, M.D., resigns as CMO effective April 10, 2023; will remain employee through April 28 for transition.
- Williams receives $580,000 base salary, 40% target bonus, and option to purchase 1,100,000 shares of common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023005548/0001564590-23-005548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023005548/sana-8k_20230410.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-005548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer